Literature DB >> 4152289

Fibrosing alveolitis and treatment with sulphasalazine.

D Davies, A MacFarlane.   

Abstract

A woman with ulcerative colitis was treated with sulphasalazine and prednisolone. After four months' treatment she began to get short of breath and she died a month later with severe subacute fibrosing alveolitis. It is believed that the lung disease was caused by sulphasalazine and that prednisolone was not able to prevent its development. A reversible form of lung disease has previously been attributed to this drug.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4152289      PMCID: PMC1412877          DOI: 10.1136/gut.15.3.185

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  6 in total

1.  Pulmonary changes associated with hexamethonium therapy.

Authors:  A G PETERSEN; M DODGE; F C HELWIG
Journal:  AMA Arch Intern Med       Date:  1959-02

2.  Sulphasalazine induced lung disease.

Authors:  G R Jones; D N Malone
Journal:  Thorax       Date:  1972-11       Impact factor: 9.139

3.  Coeliac disease and diffuse interstitial lung disease.

Authors:  M J Smith; M K Benson; I D Strickland
Journal:  Lancet       Date:  1971-03-06       Impact factor: 79.321

4.  Chronic nitrofurantoin pulmonary reaction. Report of 5 cases.

Authors:  E C Rosenow; R A DeRemee; D E Dines
Journal:  N Engl J Med       Date:  1968-12-05       Impact factor: 91.245

5.  Busulphan lung.

Authors:  B E Heard; R A Cooke
Journal:  Thorax       Date:  1968-03       Impact factor: 9.139

6.  Paraquat poisoning--lung transplantation.

Authors:  H Matthew; A Logan; M F Woodruff; B Heard
Journal:  Br Med J       Date:  1968-09-28
  6 in total
  12 in total

1.  Pulmonary vasculitis and ulcerative colitis.

Authors:  J A Forrest; D J Shearman
Journal:  Am J Dig Dis       Date:  1975-05

2.  Latent pulmonary involvement in Crohn's disease: biological, functional, bronchoalveolar lavage and scintigraphic studies.

Authors:  P Bonniere; B Wallaert; A Cortot; X Marchandise; Y Riou; A B Tonnel; J F Colombel; C Voisin; J C Paris
Journal:  Gut       Date:  1986-08       Impact factor: 23.059

Review 3.  Sulfasalazine. Adverse effects and desensitization.

Authors:  S L Taffet; K M Das
Journal:  Dig Dis Sci       Date:  1983-09       Impact factor: 3.199

4.  Bronchial disease in ulcerative colitis.

Authors:  T Higenbottam; G M Cochrane; T J Clark; D Turner; R Millis; W Seymour
Journal:  Thorax       Date:  1980-08       Impact factor: 9.139

Review 5.  Clinical pharmacokinetics of sulphasalazine.

Authors:  K M Das; R Dubin
Journal:  Clin Pharmacokinet       Date:  1976 Nov-Dec       Impact factor: 6.447

Review 6.  Drug-induced respiratory disorders: incidence, prevention and management.

Authors:  L Ben-Noun
Journal:  Drug Saf       Date:  2000-08       Impact factor: 5.606

7.  Sulfasalazine-induced pulmonary disease.

Authors:  R H Moseley; K W Barwick; K Dobuler; V A DeLuca
Journal:  Dig Dis Sci       Date:  1985-09       Impact factor: 3.199

Review 8.  Pulmonary involvement and allergic disorders in inflammatory bowel disease.

Authors:  Nikolaos E Tzanakis; Ioanna G Tsiligianni; Nikolaos M Siafakas
Journal:  World J Gastroenterol       Date:  2010-01-21       Impact factor: 5.742

9.  The association between pulmonary function impairment and colon inflammation in ulcerative colitis patients: A scientific basis for exterior-interior correlation between lung and large intestine.

Authors:  Jian-Yun Wang; Xin-Yue Wang; Hua-Yang Wu; Hui-Yi Sun; Da-Ming Liu; Wen Zhang; Chen-Xi Jin; Shuo-Ren Wang
Journal:  Chin J Integr Med       Date:  2014-06-18       Impact factor: 1.978

10.  Alveolitis associated with sulphamethoxypyridazine.

Authors:  C L Steinfort; J Wiggins; E A Sheffield; E E Keal
Journal:  Thorax       Date:  1989-04       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.